Advertisement

Journal of Molecular Neuroscience

, Volume 16, Issue 2–3, pp 309–316 | Cite as

Restoring the DHA levels in the brains of zellweger patients

  • Manuela MartinezEmail author
Article

Abstract

Patients with the Zellweger syndrome and its variants have very low levels of docosahexaenoic acid (DHA) in the brain, retina, and other tissues. Such a marked DHA deficiency could be related to the pathogenesis of peroxisomal disorders. Therefore, restoring the DHA levels in these patients can probably improve the clinical course of the disease. With this rationale, 20 patients with generalized peroxisomal disorders have been treated to date with DHA ethyl ester, at daily doses of 100–500 mg, for variable periods of time. Treatment has been always accompanied by a nutritious diet, normal for the age, in order to provide all the necessary nutrients and avoid a polyunsaturated fatty acid (PUFA) imbalance. The most constant improvement has been normalization of the DHA levels and liver function. Vision has improved in about half the patients and muscle tone has generally increased. Magnetic resonance imaging (MRI) examination revealed improvement of myelination in 9 patients. Significantly, the clinical improvement has been most marked in those patients who started the treatment before 6 mo of age. Biochemically, the plasma very long-chain fatty acids (VLCFA) 26:0 and 26:1n-9 decreased markedly despite the complete diet provided. In erythrocytes, the plasmalogen ratio 18:0DMA/18:0 increased in most cases, and sometimes even normalized. All these beneficial effects suggest that DHA deficiency plays a fundamental role in the pathogenesis of peroxisomal disease. Because DHA accretion is maximal during early brain development, it is essential to initiate the treatment as soon as possible. Otherwise, restoration of brain DHA levels and prevention of further damage will not be possible.

Index Entries

Zellweger syndrome docosahecaenoic acid arachidonic acid plasmalogens DHA therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson R. E., Benolken R. M., Dudley P. A., Landis, D. J., and Wheeler T. G. (1974) Polyunsaturated fatty acids of photoreceptor membranes. Exp. Eye Res. 18, 205–213.PubMedCrossRefGoogle Scholar
  2. Bowen P., Lee C. S. N., Zellweger H., and Lindenberg R. (1964) A familial syndrome of multiple congenital defects. Bull. Johns Hopkins Hosp. 114, 402–414.PubMedGoogle Scholar
  3. Breckenridge W. C., Gombos G., and Morgan I. G. (1972) The lipid composition of adult rat brain peroxisomal plasma memebranes. Biochim. Biophys. Acta 266, 695–707.PubMedCrossRefGoogle Scholar
  4. Bush R. A., Malnoe A., Reme C. E., and Williams T. P. (1994) Dietary deficiency of N-3 fatty acids alters rhodopsin content and function in the rat. Invest. Ophtalmol. Vis. Sci. 355, 91–100.Google Scholar
  5. Dobbing J. (1968) Vulnerable periods in developing brain, in Applied Neurochemistry (Davison A. N. and Dobbing J., eds.), Blackwell, Edinburgh, pp. 287–316.Google Scholar
  6. Gibson N. J. and Brown M. F. (1993) Lipid headgroup and acyl chain composition modulate the MI-MII equilibrium of rhodopsin in recombinant membranes. Biochemistry 32, 2438–2454.PubMedCrossRefGoogle Scholar
  7. Hajra A. K. and Bishop J. E. (1982) Glycerolipid biosynthesis in peroxisomes via de acyl dihydroxyacetone phosphate pathway. Ann. NY Acad. 386, 170–182.CrossRefGoogle Scholar
  8. Hanson R. F., Szczepanik-van Leeuwen P., Williams G. C., Grabowski G., and Sharp H. L. (1979) Defects of bile acids synthesis in Zellweger’s syndrome. Science 203, 1107–1108.PubMedCrossRefGoogle Scholar
  9. Jones C. R., Arai T., and Rapoport S. I. (1997) Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem. Res. 22, 663–670.PubMedCrossRefGoogle Scholar
  10. Lazarow P. B. and Moser H. W. (1997) Disorders of peroxisome biogenesis, in The Metabolic Basis of Inherited Disease (Scriver C. R., Beaudet A. L., Sly W. S., and Valle D., eds.), 7th CD-ROM edition, McGraw-Hill, New York, records 38,247–38,973.Google Scholar
  11. Moser A. B., Singh I., Brown F. R. III, Solish, G. I., Kelly R. I., Benke P. J., and Moser H. W. (1984) The cerebro-hepato-renal (Zellweger) syndrome: increased levels and impaired degradation of very long chain fatty acids and their use in prenatal diagnosis. N. Engl. J. Med. 310, 1141–1146.PubMedCrossRefGoogle Scholar
  12. Martinez M. (1982) Myelin lipids in the developing cerebrum, cerebellum, and brain stem of normal and undernourished children. J. Neurochem. 39, 1684–1692.PubMedCrossRefGoogle Scholar
  13. Martinez M. (1989) Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 24, 261–265.PubMedCrossRefGoogle Scholar
  14. Martinez M. (1990) Severe deficiency of docosahex-aenoic acid in peroxisomal disorders: a defect of 4-desaturation? Neurology 40, 1292–1298.PubMedGoogle Scholar
  15. Martinez M. (1992a) Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 120, S129-S138.PubMedCrossRefGoogle Scholar
  16. Martinez M. (1992b) Severe changes in polyunsaturated fatty acids in the brain, liver, kidney, and retina in patients with peroxisomal disorders, in Neurobiology of Essential Fatty Acids (Bazan N, ed.), Plenum, New York, pp. 347–359.Google Scholar
  17. Martinez M. (1992c) Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res. 583, 171–182.PubMedCrossRefGoogle Scholar
  18. Martinez M. (1992d) Treatment with docosahexaenoic acid favorably modifies the fatty acid composition of erythrocytes in peroxisomal patients, in New Developments in Fatty Acid Oxidation (Coates P. M. and Tanaka K., eds.), Wiley-Liss, New York, pp. 389–397.Google Scholar
  19. Martínez M. (1995) Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J. Inher. Metab. Dis. 18(Suppl. 1), 61–75.PubMedCrossRefGoogle Scholar
  20. Martínez M. (1996) Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis. Lipids 31, S145-S152.PubMedCrossRefGoogle Scholar
  21. Martinez M. (1998) Docosahexaenoic acid ethyl ester as a treatment for patients with generalized peroxisomal disorders, in Lipids in Infant Nutrition (Huang Y. S. and Sinclair A. J., eds.), AOCS Press, Champaign, Illinois, pp. 29–38.Google Scholar
  22. Martinez M. and Ballabriga A. (1978) A chemical study on the development of the human forebrain and cerebellum during the brain “growth spurt” period. I. Gangliosides and plasmalogens. Brain Res. 159, 351–362.PubMedCrossRefGoogle Scholar
  23. Martinez M., Conde C., and Ballabriga A. (1974) Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids. Pediatr. Res. 8, 91–102.Google Scholar
  24. Martinez M. and Mougan I. (1998) Fatty acid composition of human brain phospholipids during normal development. J. Neurochem. 71, 2528–2533.PubMedCrossRefGoogle Scholar
  25. Martinez M. and Mougan I. (1999) Fatty acid composition of brain glycerophospholipids in peroxisomal disorders. Lipids 34, 733–740.PubMedCrossRefGoogle Scholar
  26. Martinez M., Mougan I., Roig M., and Ballabriga A. (1994) Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study. Lipids 29, 273–280.PubMedCrossRefGoogle Scholar
  27. Martinez M., Pineda M., Vidal R., and Martin B. (1993) Docosahexaenoic acid: a new therapeutic approach to peroxisomal-disorder patients: experience with two cases. Neurology 43, 1389–1397.PubMedGoogle Scholar
  28. Martinez M. and Vazquez E. (1998) MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 51, 26–32.PubMedGoogle Scholar
  29. Martinez M., Vazquez E., García Silva M. T., Manzanares J., Bertran J. M., Castell F., et al. (1998) Tratamiento de las enfermedades peroxisomales generalizadas con etil ester del cido docosahexaenoico. Rev. Neurología 28, S59-S64.Google Scholar
  30. Martinez M., Vazquez E., García Silva M. T., Manzanares J., Bertran J. M., Castell F., and Mougan I. (2000) Therapeutical effects of docosahexaenoic acid in patients with generalized peroxisomal disorders. Am. J. Clin. Nutr. 71, 376S-385S.PubMedGoogle Scholar
  31. Neuringer M., Connor W. E., Lin D. S., Barstad L. and Luck S. (1986) Biochemical and functional effects of prenatal and postnatal n-3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. USA 83, 4021–4025.PubMedCrossRefGoogle Scholar
  32. Poulos A., Sharp P., Fellenberg A. J., and Danks D. M. (1985) Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy and Refsum’s disease: plasma changes and skin fibroblast phytanic acid oxidase. Human Genet. 70, 172–177.CrossRefGoogle Scholar
  33. Purpura D. P. (1975) Morphogenesis of the visual cortex in the preterm infant, in Growth and Development of the Brain (Brazier M. A. B., ed.), Raven Press, New York, pp. 33–49.Google Scholar
  34. Rotstein N. P., Politi L. E., and Aveldaño M. I. (1998) Docosahexaenoic acid promotes differentiation of developing photoreceptors in culture. Invest. Opthalmol. Vis. Sci. 39, 2750–2758.Google Scholar
  35. Subramani S. (1998) Components involved in peroxisome import, biogenesis, proliferation, turnover, and movement. Physiol Rev. 78, 171–188.PubMedGoogle Scholar
  36. Santos M. J., Imanaka T., Shio H., Small G. M., and Lazarow P. B. (1988) Peroxisomal membrane ghosts in Zellweger syndrome: aberrant organelle assembly. Science 239, 1536–1538.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  1. 1.Unit for Research in Biochemistry and Molecular BiologyMaternity-Children’s Hospital Vall d’HebronBarcelonaSpain

Personalised recommendations